Nitric oxide (NO), is endogenously synthesized from L-arginine by nitric oxide synthase (NOS), exhibits a dual role in sensitivity to radiotherapy and chemotherapy of cancer cells. The aim of this study was to evaluate the influence of polymorphisms in NOS genes on treatment response of non-small-cell lung cancer (NSCLC) patients after radiochemotherapy.
Worldwide, lung cancer is the most common cause of cancer-related death in men and women, and is responsible for 1.4 million deaths annually, as of 2008 [1] . Most patients diagnosed with non-small cell lung cancer (NSCLC) presented with advanced disease. For these patients, chemotherapy and radiotherapy were often the primary choices of treatment. Although platinum-based chemotherapy alone or in combination with radiotherapy is effective in treating some patients, insensitivity to radiochemotherapy is still a major problem in cancer treatment [2] and usually predicted shorter overall survival [3] . The basis behind treatment resistance either as primary or secondary, i.e., occurring after an initial treatment response, is still challenging to understand [4] . In previous studies, genetic factors were proved to influence the effectiveness of lung cancer treatment [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .
Nitric oxide (NO), a reactive radical, is endogenously synthesized from L-arginine by nitric oxide synthase (NOS), which exists as three isoforms: neuronal NOS (nNOS/NOS1), inducible NOS (iNOS/NOS2), endothelial NOS (eNOS/ NOS3) [15] . The nNOS and eNOS isoforms are constitutively expressed in a variety of cell types including the endothelium, platelets, and neurons [16] . However, iNOS is absent in resting cells, but is capable of being rapidly expressed in response to proinflammatory stimuli such as cytokines and the HIF-1 mediated pathway [17] . In cancer biology and treatment, NO may have dual effects [18] , cytoprotective and cytotoxic, which depended upon NO concentrations [19] or the specific gene, such as P53 [20] . On the one hand, NO is considered as an efficient hypoxic radiosensitizer [21] [22] [23] [24] [25] [26] [27] or a chemosensitizer [28] [29] [30] . Further studies suggested that iNOS overexpression by adenoviral gene delivery enhances the radioresponsiveness of colorectal cancer via p53 activation and caspase-dependent apoptotic mechanism [30] [31] [32] [33] . On the other hand, NO radicals could contribute to the induction of radioresistance [34] and chemotherapeutic resistance [35, 36] . In lung cancer patients, several cytokines (IL-1β, IL-6, IFN-γ, TNF-α, TGF-β, etc.) are produced to enhance the production of NO [37] . These studies suggest that NO and NOS may be a novel therapeutic strategy for NSCLC treatment.
Given the uncertainty between NOS and treatment response, we speculated that genetic variants in NOS genes may alter their expression, activity or functions and in turn influence the effects of cancer treatment. To test this hypothesis, we genotyped 198 specimens collected from a cohort of NSCLC patients for 35 single nucleotide polymorphisms (SNPs) in NOS2A and NOS3 genes by using the Sequenom MassArray system, and then evaluated their associations with radiochemotherapy sensitivity. The result is expected to guide individualized NSCLC therapy.
Patients and Methods

Patient Population and Clinical Data Collection.
In this study, a total of 198 DNA samples available from newly diagnosed lung cancer patients were prospectively collected between December 2009 and January 2011 at Radiation Oncology Department in Shandong Cancer Hospital (Jinan). All patients were Chinese and were diagnosed with histologically confirmed locally advanced (stage III) or advanced (stage IV) NSCLC, Karnofsky performance status (KPS) ≥60, and an expected survival of >6 months. Each patient signed an informed consent and was entered into the clinical research database prior to study entry. This study was approved by Shandong Cancer Hospital institutional review board. The clinical information including sex, age, histology, performance status, smoking status, clinical stage, tumor location, total radiation dose, radiotherapy technique (two-or three-dimension), chemotherapy or other factors were collected. Patient responses to treatment including complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) were determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 [38] . For data analysis, CR and PR were combined as responders, and SD and PD were grouped as non-responders.
Radiotherapy. All patients received radiotherapy with 6-MV X-rays from linear accelerators (21EX, 23EX or Trilogy; Varian Inc., CA, USA). Target volumes were defined according to the report of International Commission on Radiological Units. The gross tumor volume (GTV) included the primary disease plus any involved regional lymph nodes. The planning target volume (PTV) was considered to include the GTV plus a 10-to 15-mm margin. 95% isodose line encompassed the PTV. Planning objective for total lung receiving > 20 Gy (V 20 SNP Selection. We chose tag SNPs according to a similar approach in the previous article [39] . Tag SNPs were selected based on the ability to tag surrounding variants (iNOS, chr17 and eNOS, chr7) in the Han Chinese panel (Beijing, China) of the International HapMap project, NCBI build B36 assembly HapMap phase II+III (http://www.hapmap.org). The region used in tagSNP selection included a region from 3,000 bp 5' upstream to 1000 bp 3' downstream of NOS2A or NOS3. Tagger software included in Haploview software 4.2 was used to select tag SNPs. The pairwise algorithm of the Tagger program was used to select the tags. An r 2 of 0.8 was defined as the coefficient threshold for tag selection and minor allele frequency (MAF) was 0.05 [40] . In addition, common SNPs based on previous report of other diseases in NOS were included in this study. The characteristics of 35 selected SNPs were listed in Table 1 .
DNA Collection and Genotyping. A 1mL whole-blood sample was obtained from each patient before treatment. The blood samples were collected in EDTA vacutainer tubes and stored at −80°C until analysis. Genomic DNA was extracted from whole-blood cells using AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, USA) according to the manufacturer's instructions. The DNA purity and concentration were determined by spectro-photometric measurement of absorbance at 260 and 280 nm, respectively. Approximately 25 ng of genomic DNA was used to genotype each sample using the Sequenom MassArray system (San Diego, USA). The sample DNA was amplified by multiplex PCR reaction and the PCR products were then used for single-base extension reaction. The resulting products were desalted and transferred to a 384-element SpectroCHIP array. Allele detection was performed using MALDI-TOF MS. The mass spectrograms were analysed by the Sequenom MassARRAY TYPER software (San Diego, USA). The whole SNPs genotyping was conducted at Shandong Provincial Key Lab for Dermatovenereology (Jinan, China).
Statistical Analysis. The frequencies of different genotypes were compared between patients with and without treatment response through the Chi-square test. In multivariate analyses, unconditional logistic regression was performed to assess the association between treatment response and each genotype while adjusting for other covariates, including radiation dose, sex, age, histology, performance status, smoking status, clinical stage, tumor location, chemo-radiotherapy type. In the regression analysis, the dependent variable was patient response to treatment; patients who did not respond to treatment (SD + PD) were compared to patients who responded to treatment (CR + PR). Odds ratios (OR) and their corresponding 95% confidence intervals (CI) were calculated using the logistic regression model. P value <0.05 was considered statistically significant. All tests were two-sided. Statistical analysis was performed using IBM SPSS statistical version 19.0 software.
Results
Clinical Characteristics. Abbreviations: KPS, karnofsky performance status; NSCLC, NOS, non-smallcell lung carcinoma, not otherwise specified; CSI, cigarette-smoke index; IMRT, intensity-modulated radiation therapy.
therapy dose (≥60 Gy) was shown to have a higher response than those treated with lower ones (53.8% versus 29.6%, P = 0.001). The response rates among all the treatment groups with different chemotherapy regimens were not significantly different (P = 0.221). The response rate to treatment for the patients with stage III NSCLC was higher than those with stage IV, but the difference was not statistically significant (49.1% versus 38%, P = 0.119). Associations between clinical characteristics and treatment response were shown in Table 3 . Genotypes and Treatment Responses. Successful genotype call rates in 35 SNPs were 97-100% and no SNP was excluded from analysis. Genotype distributions of 35 SNPs in NOS3 and NOS2A genes and association analysis results were listed in Table 4 , Table 5 , respectively. We observed no significant associations between treatment response and each genotype. It was noted that treatment responders and non-responders differed obviously with respect to radiation dose. While adjusting for covariates in the multiple logistic regression analysis, the associations were also not significant.
Discussion
The aim of this study is to investigate the association between genetic variants of NOS and treatment response. Our results suggest that single nucleotide polymorphisms in NOS2A and NOS3 genes are not associated with treatment response of NSCLC patients following radiochemotherapy. Even after adjusting for other covariates, no significant associations were found. On one hand, this negative result was possibly due to: (i) There was a small cohort of patients analyzed. Whenever a negative association study is reported, the power of the study is normally questioned. On this regard we speculate that smaller sample size may be a limiting factor for this study especially for the analysis of treatment effects where we are comparing 87 responders against 111 non-responders.
(ii) The role of genetic variants of NOS2A and NOS3 on treatment response may be covered by other clinical or dosimetric factors, such as stage, chemotherapy regimens, radiation dose, etc. On the other hand, since NO and NOS might have totally diverse biological effects on chemoradiotherapy and the evidence in cancer is also conflicting, the hypothesis that NOS gene is responsible for the differences in treatment response of NSCLC patients may be incorrect. In view of the two possible aspects, the large sample validation study is necessary in the future.
In previous studies, genetic factors had been proved to influence the effectiveness of lung cancer treatment [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Over the past few years, associations between NOS polymorphisms and clinical prognosis of patients with breast cancer, vulvar cancer and NSCLC had also been reported [14, [41] [42] [43] . The polymorphism of the 27-bp variable number of tandem repeats (VNTR) in intron 4, not G894T in exon 7 (rs1799983) of the eNOS gene was found to be an independent prognostic factor for survival in advanced stage NSCLC patients treated with standard platinum-based chemotherapy [14] . However, the author continued to analyze the treatment response among patients without definitive thoracic radiotherapy, indicating that the effect of the polymorphism on survival was not associated with treatment response [14] . The present study, revealed that there was no association between rs1799983 of the eNOS gene and treatment response in NSCLC patients, was consistent with this study.
Strength of this study is the inclusion of a considerable number of SNPs for which an association with cancer is biologically plausible and/or has been previously reported. However, our study has several limitations. Firstly, because we selected the most informative SNPs with high MAF and r 2 , some causal variants might be missed. Secondly, the single-institutional study design contains the potential to introduce a selection bias. Thirdly, the analysis based upon a small number of enrolled patients could potentially lead to false-negative results. Finally, because all patients in our study were Han Chinese, it is uncertain whether these Abbreviations: OR, odds ratios; 95%CI, 95% confidence intervals; KPS, karnofsky performance status; COPD, chronic obstructive pulmonary disease; NSCLC, NOS, non-small-cell lung carcinoma, not otherwise specified; CSI, cigarette-smoke index; CRT, concurrent chemoradiation.
results can be generalized to other populations. Because ethnic differences in the genotypes in NOS genes may exist, other studies in different population are required to confirm such results.
Conclusions
To our knowledge, this is the comprehensive report investigating the association between genetic polymorphisms of 
